UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
Key Details
- 1AI stratified patients by tumor cell density on diagnostic biopsy slides in a post-hoc ARISTOTLE phase III trial analysis (n=414).
- 2Adding irinotecan reduced recurrence by 43% and death by 50% over 5 years in high-tumor-cell-density cases; no benefit in low-density cases.
- 3AI tool ('Octopath') enables rapid, large-scale analysis of digital pathology slides.
- 4Manual quantification was previously impractical for large studies; automation enables scalable, individualized treatment decisions.
- 5Further verification and studies are needed before clinical deployment.
Why It Matters
AI-driven analysis of biopsy pathology can enable more precise, personalized cancer therapy selection, sparing patients from unnecessary side effects and improving survival. This study underscores AI's value in digital pathology for oncology decision-making.
Source
EurekAlert
Related News
•EurekAlert
Debate Intensifies: Autonomous AI vs. Physician-Led Care in Medicine
A new perspective piece explores whether autonomous AI could outperform physician-led care in clinical settings.
•EurekAlert
AI 'Tissue Clocks' Estimate Organ-Specific Biological Age from Images
Researchers developed AI models that estimate the biological age of human organs from histological images, revealing organs age at different rates.
•EurekAlert
AI-Powered 3D Intraoperative Imaging Transforms Glioma Surgery
Researchers develop ULTRA, an AI-driven platform enabling 3D intraoperative tissue imaging for detecting glioma infiltration within 30 minutes.